Biotech | April 11, 2022
Lonza signs manufacturing deal with Asher Biotherapeutics
Under the manufacturing agreement, Lonza will provide drug substance for Asher Bio's cis-targeted IL-2 fusion protein
Under the manufacturing agreement, Lonza will provide drug substance for Asher Bio's cis-targeted IL-2 fusion protein
The site consists of five fermentation "mini-factories" capable of concurrently producing our more than 13 currently scaled and future bio-fermented products
Results from pre-clinical research show iron-like compound hold promise for treating patients with glioblastoma, an aggressive brain cancer
Although PCM has advanced substantially in recent years, most of the valuable technical information resides with private companies and academic publications across multiple platforms
Essent continues to broaden its highly characterized, low passage primary cell catalog
Collaboration to target bacterial and viral pathogens including HIV, SARS-CoV-2, antimicrobial-resistant pathogens, and tuberculosis
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
If authorized by the USFDA, the Proof Lab Test System may be used to deliver accurate, actionable, lab-quality results for Covid-19 in as little as 18 minutes
The new unit will be built with INEOS’ latest process technology and aims to substantially improve the sustainability of our supply to our customers and reduce our environmental impact
About 96% of all 15+ population in the country have received at least one Covid-19 vaccine dose while about 83% of 15+ population has received both the doses
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
